NCT07717879Phase 3Recruiting

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

Study sponsor: Axsome Therapeutics, Inc. · AXSM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06-30Estimated
Enrollment · participants468Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.